Drug development company Ellipses Pharma now has more than 200 oncology experts from 106 institutions worldwide providing analysis and advice on selection of the most promising potential cancer medicines in its Scientific Affairs Group (SAG).
The number of experts joining the SAG has increased by 53% in the last nine months and now comprises 129 specialists in Europe, 53 in the United States and 19 in the Asia-Pacific (APAC) and Middle East-North Africa (MENA) geographies.
The latest oncologists to join the SAG include:
- A Nobel Prize Laureate and Professor of Medicine at Johns Hopkins School of Medicine (USA),
- a pioneer in breast cancer therapy who is also a Diplomate of the American Board of Internal Medicine & National Board of Medical Examiners,
- an ovarian cancer expert and senior faculty member of the Leuven Cancer Institute (Belgium) who is one of the most published individuals for ovarian cancer and recipient of the Norwegian Kolstad, the Netherlands COBRA, and the Austrian Wertheim prizes, all for excellence in oncology.
Professor Sir Christopher Evans, OBE, Chairman, Ellipses Pharma, said: “We are delighted and very proud that so many eminent oncologists from around the world have enthusiastically embraced what we believe is the largest scientific affairs group in oncology and a unique model. From the outset, our goal has been to streamline the cancer drug development process and our key opinion leaders are playing a vital role in helping us de-risk drug selection and advance high-quality assets quickly.”
